Carfilzomib is a proteasome inhibitor used to treat multiple myeloma, a type of blood cancer. It works by inducing apoptosis in cancer cells through proteasome inhibition. This medication is crucial for managing specific types of blood cancers. In summary, Carfilzomib is effective in treating multiple myeloma.
Carfilzomib inhibits the proteasome, leading to the accumulation of pro-apoptotic factors and subsequent cancer cell death.
No published brands for this salt yet.